

Apr 28, 2023

# **6** Molecular Diagnosis of Viral Hepatitis B Infection

DOI

dx.doi.org/10.17504/protocols.io.kqdg39ozeg25/v1



# Frank Twum Aboagye<sup>1</sup>, Maame Ekua Acquah<sup>2</sup>

<sup>1</sup>Biomedical and Public Health Research Unit, CSIR - Water Research Institute;

<sup>2</sup>West African Centre for Cell Biology of Infectious Pathogens, College of Basic and Applied Sciences, University of Ghana, Legon, Accra, Ghana



### Frank Twum Aboagye

Biomedical and Public Health Research Unit, CSIR - Water Res...

## Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account





DOI: https://dx.doi.org/10.17504/protocols.io.kqdg39ozeg25/v1

**Protocol Citation:** Frank Twum Aboagye, Maame Ekua Acquah 2023. Molecular Diagnosis of Viral Hepatitis B Infection. **protocols.io** <a href="https://dx.doi.org/10.17504/protocols.io.kqdg39ozeg25/v1">https://dx.doi.org/10.17504/protocols.io.kqdg39ozeg25/v1</a>



**License:** This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: April 14, 2023

Last Modified: April 28, 2023

Protocol Integer ID: 80544

**Keywords:** Viral Hepatitis, Hepatitis B, RT-PCR, DNA Extraction, Infectious Diseases, step process of hbv diagnosis, hbv dna, hbv detection, hbv diagnosis, bosphore hbv quantitative kit, hbv infection, molecular diagnostic technique, bosphore hbv quantitative kit for amplification, immunological assay approach, bosphore hbv quantitative kit on several thermocycler, molecular diagnosis, low antigen titers in study sample, immune detection, limitations of immune detection, viral genome, low antigen titer, sensitive tool for diagnosis, pcr, mutation in the viral genome, nucleic acid, nuclei acid isolation, high nuclei acid yield from isolation

#### **Funders Acknowledgements:**

Inqaba Biotech West Africa Limited (http://www.inqababiotec.ng)

**Grant ID: NA** 

### Disclaimer

This is an optimized protocol for the quantitative detection of Hepatitis B using Zymo Quick-DNA Miniprep Kit (200 prep) and Bosphore HBV Quantitative Kit. The authors do not accept any liability for the collection and handling of both samples and reagents, results from the use of the protocol and its interpretation as well as any errors or omissions that may be made. The reader should make his/her own evaluation as to the appropriateness of the procedures described.



### Abstract

With over 400 million HBV infections, viral hepatitis B remains a global public health concern. Diagnosis is primarily based on an immunological assay approach, which utilizes the Hepatitis B surface antigen in detection amongst other markers. This method, however, has several limitations which include the inability to detect mutation in the viral genome resulting in diagnostic escape and low antigen titers in study samples. Using an alternative approach, which is the molecular diagnostic technique such as real-time polymerase chain reaction (RT-PCR) would circumvent the limitations of immune detection. This protocol, thus, provides a stepby-step process of HBV diagnosis using RT-PCR which is a sensitive tool for diagnosis. The steps involved include sample collection and preparation, nuclei acid isolation, HBV detection and quantification using RT-PCR as well as the interpretation of results.

This protocol combines the high nuclei acid yield from isolation using Zymo Quick DNA Mini-prep Kit and Bosphore HBV Quantitative Kit for amplification of HBV DNA. The Bosphore HBV Quantitative Kit has a low detection limit of 1×10<sup>1</sup> IU/ml and with a turn-around time of less than 4 hours when combined with Zymo Quick DNA Mini-prep Kit. The nucleic acid isolated in this protocol can be amplified using the Bosphore HBV Quantitative kit on several thermocyclers, which makes the protocol robust, cost-efficient, and cost-effective in resource-scarce areas.

## Image Attribution

https://www.anatoliageneworks.com/en/diseases/hepatitis-b/

## Guidelines

Reagent Preparation for Nucleic Acid Isolation Nucleic Acid Isolation Detection and Quantification of HBV Nucleic Acid Results and Interpretation Troubleshooting



### **Materials**

### Consumables

- 1. Microcentrifuge tube (1.5 ml)
- 2.  $100 1000 \mu l$  filtered tips
- 3.  $20 200 \mu l$  filtered tips
- 4.  $5 20 \mu l$  filtered tips
- 5. 96-well PCR plate or 8-well PCR strip
- 6. Permanent marker

### Reagents

- 1. ZYMO Quick DNA Miniprep Kit
- 2. Bosphore HBV Quantitative Kit (Includes internal control, standards (4), PCR master mix, positive control and nuclease-free water)
- 3. Absolute Ethanol (Molecular Grade)
- 4. Proteinase K

### **Equipment**

- 1. Thermocycler (Real-Time PCR)
- 2. Incubator
- 3. Vortex
- 4. Microcentrifuge

# **Troubleshooting**

# Safety warnings



- 1. Handle all blood specimens and reagents as a potential biohazard.
  - 2. Discard all waste materials in the appropriate receptacles.
  - 3. β-mercaptoethanol has a pungent smell, it should be opened in a well-aerated space.
  - 4. Ensure the use of the appropriate PPEs at all times



### Before start

### **Sample Collection and Preparation**

Aseptically collect venous blood from the antecubital vein of the forearm and dispense it into either a serum separator tube (SST), a plain tube (red top), or an EDTA tube (plasma).

Centrifuge the specimen at 3500 rpm for 10 minutes and transfer the serum or plasma into a sterile plain tube or a cryovial.

#### NB:

For samples collected into SST or plain tubes, allow the specimen to stand vertically undisturbed for at least 1 hour for the specimen to clot completely before centrifuging it to yield serum

Samples collected into EDTA tubes can be centrifuged immediately to yield plasma.

Care should be taken during sample collection and processing to avoid haemolysis of the specimen

### **Handling of PCR Reagents**

Allow the PCR Master Mix and the other components of the Bosphore HBV Quantification kit to thaw completely at 4°C before use and avoid centrifuging to thaw.



9

# Reagent Preparation for Nucleic Acid Isolation

Add  $\Delta$  500 μL of β-mercaptoethanol to  $\Delta$  100 mL of Genomic Lysis Buffer

Note

Cap the bottle tightly after each use

# **HBV Nucleic Acid Isolation** 5h 2m 2 Transfer △ 200 µL of ß serum/plasma to a sterile △ 1.5 mL microcentrifuge tube (pre-labeled). 3 Add 4 5 µL of Internal Control (provided with the amplification kit) to each specimen 30s and vortex for 🚫 00:00:30 4 Add $\perp$ 400 $\mu$ L of Genomic Lysis Buffer and $\perp$ 10 $\mu$ L of Proteinase K to the sample. 5 Vortex and incubate the sample at \$\infty\$ 56 °C for 3 - 5 hours or Overnight . 5h 6 Vortex the sample at (5 3000 rpm for (5) 00:00:30 30s 7 Transfer the entire content of the 1.5 ml microcentrifuge tube into a Zymo-Spin IIC Column in a collection tube. 8 Centrifuge at 10000 rpm for 00:01:00 . Discard the flow-through liquid. 1m

Transfer the Zymo-Spin IIC column into a new collection tube.



- 10 Add 🚨 200 µL of DNA Pre-Wash Buffer to the spin column and centrifuge 1m 10000 rpm for 00:01:00 . Discard the flow-through liquid. 11 10. Add Δ 500 μL of gDNA Wash Buffer to the spin column and centrifuge at 1m 10000 rpm for 00:01:00 . Discard the flow-through liquid. 12 11. Transfer the Zymo-Spin IIC Column into a sterile 1.5 mL microcentrifuge tube 13 12. Add  $\perp$  100  $\mu$ L (70 - 100) of DNA Elution Buffer to the spin column and incubate at 30m Room temperature for 00:30:00 14 13. Centrifuge at 13000 rpm for 00:00:30 to elute the DNA. 30s
- 13. Centinuge at 13000 rpm for 600.00.30 to educe the DNA.
- 15 14. Store the Viral Nucleic acid at -20 °C pending further analysis.

## RT-PCR Detection and Quantification of HBV Nuclei Acid

The PCR is done in a  $\stackrel{\square}{=}$  25  $\mu$ L reaction as described below:

| А  | В       |
|--|---------|
| Reagent/Component  | X1 (μL) |
| PCR Master mix   | 15      |
| Test Nucleic acid/Standards/Negative Control/Positive<br>Control | 10      |
| Total Reaction Volume  | 25 μL   |

Allow the PCR Master Mix and the other components of the Bosphore HBV Quantification kit to thaw completely at 4°C before use and avoid centrifuging to thaw.

17 The reaction is done under the following cycling conditions:






| А   | В                    | С                 | D            |
|---|----------------------|-------------------|--------------|
| Step                                      | Temperatur<br>e (°C) | Time<br>(minutes) | Cycles       |
| Initial Denaturation                      | 95                   | 14:30             | NA           |
| Denaturation                              | 97                   | 00:30             | 50<br>cycles |
| Annealing and Synthesis (Data Collection) | 54                   | 01:30             | Cycles       |
| Hold                                      | 32                   | 01:00             | NA           |

18 Select the appropriate fluorophore depending on the analyzer been used. For Bio-Rad CFX 1000 Series, select the FAM dye for HBV and HEX for Internal Control (IC).



|   | 1           | 2           | 3           | 4           | 5           |
|---|-------------|-------------|-------------|-------------|-------------|
| Α | FAM and HEX |
| В | FAM and HEX |
| С | FAM and HEX |
| D | FAM and HEX |
| E | FAM and HEX |
| F | FAM and HEX |
| G | FAM and HEX |
| н | FAM and HEX |
|   | 1           | 2           | 3           | 4           | 5           |
| Α | FAM and HEX |

| В | FAM and HEX   | FAM and HEX     | FAM and HEX | FAM and HEX | FAM and HEX |
|---|---------------|-----------------|-------------|-------------|-------------|
| С | FAM and HEX   | FAM and HEX     | FAM and HEX | FAM and HEX | FAM and HEX |
| D | FAM and HEX   | FAM and HEX     | FAM and HEX | FAM and HEX | FAM and HEX |
| E | FAM and HEX   | FAM and HEX     | FAM and HEX | FAM and HEX | FAM and HEX |
| F | FAM and HEX   | FAM and HEX     | FAM and HEX | FAM and HEX | FAM and HEX |
| G | FAM and HEX   | FAM and HEX     | FAM and HEX | FAM and HEX | FAM and HEX |
| Н | FAM and HEX   | FAM and HEX     | FAM and HEX | FAM and HEX | FAM and HEX |
|   | 1             | 2               |             |             |             |
|   | A FAM and HEX | FAM and HEX     | 3           |             |             |
|   | B FAM and HEX |                 |             |             |             |
|   | C FAM and HEX | () (FAM and HEX | (c)         |             |             |



19 Identify unknown samples (test samples), standards, positive control, and negative control on the plate as described below. Assign the right quantitative values to the standards

|   | 1       | 2       | 3       | 4       | 5       |
|---|---------|---------|---------|---------|---------|
| Α | Unknown | Unknown | Unknown | Unknown | Unknown |
| В | Unknown | Unknown | Unknown | Unknown | Unknown |
| С | Unknown | Unknown | Unknown | Unknown | Unknown |
| D | Unknown | Unknown | Unknown | Unknown | Unknown |
| E | Unknown | Unknown | Unknown | Unknown | Unknown |
| F | Unknown | Unknown | Unknown | Unknown | Unknown |
| G | Unknown | Unknown | Unknown | Unknown | Unknown |
| н | Unknown | Unknown | Unknown | Unknown | Unknown |
|   | 1       | 2       | 3       | 4       | 5       |
| А | Unknown | Unknown | Unknown | Unknown | Unknown |

| B Unknown Unknown Unknown Unknown |
|-----------------------------------|
| C Unknown Unknown Unknown Unknown |
| D Unknown Unknown Unknown Unknown |
| E Unknown Unknown Unknown Unknown |
| F Unknown Unknown Unknown Unknown |
| G Unknown Unknown Unknown Unknown |
| H Unknown Unknown Unknown Unknown |
| 1 2                               |
| A Unknown Negative Control        |
| B Unknown                         |
| C Unknown Standard 1              |



20 Initiate the protocol

# **Results and Interpretation**

21

Samples that cross the threshold in the FAM channel are displayed with their starting quantities and the corresponding Ct-values. Samples that do not cross the threshold are displayed as "No Ct" or " –"

### 22 Possible outcomes from the PCR:

| Α | В | С             | D  |
|---|---|---------------|--|
| + | - | HBV Positive  | The sample contains a high viral load of HBV and may suppress the amplification of the Internal Control. No need to check the HEX  |
| + | + | HBV Positive  | The sample contains HBV Nucleic acid   |
| + | - | HBV Positive* | Caution: If the sample has a viral load <10 IU/ml and no Internal Control amplification, it indicates PCR inhibition which requires assay repetition (see troubleshooting) |
| - | + | HBV Negative  | No HBV Nucleic acid was detected. Internal control amplified indicating good DNA isolation and PCR procedures.   |
| - | - | Invalid**     | Repeat the assay (see troubleshooting)   |

<sup>\*</sup> and \*\*: refer to the troubleshooting section

# Troubleshooting

\*If the sample has a viral load [M] <10 IU/ml and no Internal Control amplification, it requires that the assay is repeated once. Freeze-thaw[freeze the sample (temperature ≤ -10°C) for 20 minutes and defrost at room temperature for 10 minutes] the nucleic acid sample and dilute it with nuclease-free water in a ratio of 1:2. Use the diluted nucleic acid for repeating the assay

\*\* Repeat the assay once taking into consideration possible pipetting errors in the first assay.



If both repeat as indicated above fail to yield the expected/better results, a new specimen should be collected from the patient and the process from nucleic acid isolation to amplification should be repeated with the new sample.

## Protocol references

Datta, S., Chatterjee, S., & Veer, V. (2014). Recent advances in molecular diagnostics of hepatitis B virus. World Journal of Gastroenterology, 20(40), 14615-14625. https://doi.org/10.3748/wjg.v20.i40.14615 Lin, N., Ye, A., Lin, J., Liu, C., Huang, J., Fu, Y., ... & Ou, Q. (2020). Diagnostic value of detection of pre-genomic RNA in sera of hepatitis B virus-infected patients with different clinical outcomes. Journal of clinical microbiology,58(2), e01275-19. Journal of clinical microbiology,58(2), e01275-19.